Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Fc (human):FasL, Soluble (human) (rec.)
335
CHF
CHF 335.00
In stock
AG-40B-0132-C01010 µgCHF 335.00
AG-40B-0132-30103 x 10 µgCHF 670.00
Figure 1: Oligomerisation of FasL (h) efficiently triggers Jurkat cell death.
Method: Jurkat cells were treated O/N with the indicated concentrations of MegaFasL, Soluble (human) (rec.) (Prod. No. AG-40B-0130), Fc:FasL, Soluble (human) (rec.) (Prod. No. AG-40B-0132), FasL, Soluble (human) (rec.) (Prod. No. AG-40B-0001) or FasL, Soluble (human) (rec.) + TNF ligands enhancer (Prod. No. AG-44B-0001) (2 fold-dilutions, first concentration of 1000ng/ml). Cell death was quantified using PMS/MTS. The oligomeric FasL recombinant proteins (MegaFasL, Soluble (human), Fc:FasL, Soluble (human) and FasL, Soluble (human) + TNF ligands enhancer) kill Jurkat cells at IC50 <0.2ng/ml.
Method: Jurkat cells were treated O/N with the indicated concentrations of MegaFasL, Soluble (human) (rec.) (Prod. No. AG-40B-0130), Fc:FasL, Soluble (human) (rec.) (Prod. No. AG-40B-0132), FasL, Soluble (human) (rec.) (Prod. No. AG-40B-0001) or FasL, Soluble (human) (rec.) + TNF ligands enhancer (Prod. No. AG-44B-0001) (2 fold-dilutions, first concentration of 1000ng/ml). Cell death was quantified using PMS/MTS. The oligomeric FasL recombinant proteins (MegaFasL, Soluble (human), Fc:FasL, Soluble (human) and FasL, Soluble (human) + TNF ligands enhancer) kill Jurkat cells at IC50 <0.2ng/ml.
Product Details | |
---|---|
Synonyms | APO-1L; CD95L; CD178; TNFSF6; Fas Ligand |
Product Type | Protein |
Properties | |
Source/Host | HEK 293 cells |
Sequence |
Human FasL (aa 139-281) is fused at the N-terminus to the Fc portion of human IgG1. |
Crossreactivity |
Human Mouse |
Specificity |
Binds to human and mouse Fas. |
Biological Activity |
Induces apoptosis of human Jurkat T cells at a concentration of <0.2ng/ml. |
MW | ~50kDa (SDS-PAGE) |
Purity | ≥95% (SDS-PAGE) |
Endotoxin Content | <0.01EU/μg purified protein (LAL test). |
Concentration | 0.1mg/ml after reconstitution. |
Reconstitution | Reconstitute with 100μl sterile water. |
Formulation | Lyophilized. Contains PBS. |
Protein Negative Control | |
Other Product Data |
UniProt link P48023: FasL (human) |
Shipping and Handling | |
Shipping | BLUE ICE |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice |
After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. PBS containing at least 0.1% BSA should be used for further dilutions. |
Use/Stability |
Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
Documents | |
MSDS | Download PDF |
Product Specification Sheet | |
Datasheet | Download PDF |
Description
Fc (human):FasL, Soluble (human) is a high activity construct in which two trimeric FasL are artificially linked via the Fc binding domain of human IgG1. This construct very effectively simulates the natural membrane-assisted aggregation of FasL in vivo. FasL is a cytokine that binds to TNFRSF6/Fas, a receptor that transduces the apoptotic signal into cells. It is involved in cytotoxic T cell mediated apoptosis and in T cell development.
Product References
- Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex: N. Holler, et al.; Mol. Cell. Biol. 23, 1428 (2003)
- Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C: Y.P. Zhu, et al.; J. Clin. Invest. 131, e147076 (2021)
- NET formation is a default epigenetic program controlled by PAD4 in apoptotic neutrophils: Y.P. Zhu, et al.; Sci. Adv. 9, 1397 (2023)